Rational development of addiction pharmacotherapies: Successes, failures, and prospects

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 6, 2012, Pages

  Pierce, R Christopher ^a   O'Brien, Charles P ^a   Kenny, Paul J ^b   Vanderschuren, Louk J M J ^c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACAMPROSATE; ACETYLCYSTEINE; ALCOHOL; ALDEHYDE DEHYDROGENASE; AMFEBUTAMONE; BUPRENORPHINE; COCAINE; DEPADE; METHADONE; NALOXONE; NALTREXONE; NICOTINE; NICOTINIC RECEPTOR; OPIATE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; VARENICLINE; DRUGS USED IN THE TREATMENT OF ADDICTION; NARCOTIC ANTAGONIST; NICOTINIC AGENT;

ADDICTION; ALCOHOLISM; ARTICLE; DOPAMINE RELEASE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG FORMULATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROTRANSMISSION; NONHUMAN; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; TOBACCO DEPENDENCE; TOBACCO USE; VACCINATION; WITHDRAWAL SYNDROME; METHODOLOGY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; REVIEW;

ANIMALIA;

ALCOHOL DETERRENTS; ALCOHOLISM; HUMANS; NARCOTIC ANTAGONISTS; NICOTINIC AGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 84879829682     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012880     Document Type: Article

References (57)

1. Altshuler HL, Phillips PE, Feinhandler DA. 1980. Alteration of ethanol self-administration by naltrexone. Life Sci 26: 679-688.
2. Baker DA, Shen H, Kalivas PW. 2002. Cystine/glutamate exchange serves as the source for extracellular glutamate: Modifications by repeated cocaine administration. Amino Acids 23: 161-162.
3. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. 2003. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann NY Acad Sci 1003: 349-351.
4. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M. 2005. Increased attributable risk related to a functional μ-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30: 417-422.
5. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, Durlach J. 1984. A homotaurine derivative reduces the voluntary intake of ethanol by rats: Are cerebral GABA receptors involved? Pharmacol Biochem Behav 21: 787-789.
6. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, et al. 1998. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci 95: 9608-9613.
7. Clark R, Schuster CR, Brady JV. 1961. Instrumental conditioning of jugular self-infusion in the rhesus monkey. Science 133: 1829-1830.
8. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, DavisTI, Lebel LA, Fox CB, et al. 2005. Varenicline: Anα4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
9. Dahchour A, De Witte P. 2000. Ethanol and amino acids in the central nervous system: Assessment of the pharmacological actions of acamprosate. Prog Neurobiol 60: 343-362.
10. De Witte P, Littleton J, Parot P, Koob G. 2005. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs 19: 517-537.
11. Dole VP, Nyswander M. 1965. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 193: 646-650.
12. Feltenstein MW, Altar CA, See RE. 2007. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 61: 582-590.
13. Ferno O. 1973. A substitute for tobacco smoking. Psychopharmacologia 31: 201-204.
14. Ferno O. 1994. Conversation with OveFerno. Addiction 89: 1215-1226.
15. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J. 1990. Smoking, smoking cessation, and major depression. JAMA 264: 1546-1549.
16. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. 2006. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296: 47-55.
17. Goode PG. 1971. An implanted reservoir of morphine solution for rapid induction of physical dependence in rats. Br J Pharmacol 41: 558-566.
18. Haney M, Spealman R. 2008. Controversies in translational research: Drug self-administration. Psychopharmacology (Berl) 199: 403-419.
19. Haney M, Ward AS, Foltin RW, Fischman MW. 2001. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology (Berl) 155: 330-337.
20. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. 2010. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59-65.
21. Haney M, Rubin E, Foltin RW. 2011. Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology (Berl) 216: 379-387.
22. Heilig M, Egli M. 2006. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 111: 855-876.
23. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, et al. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202.
24. Isbell H, Wikler A, et al. 1947. Tolerance and addiction liability of 6-dimethylamino-4-4-diphenylheptanone-3 (methadon). J Am Med Assoc 135: 888-894.
25. Jarvis MJ, Raw M, Russell MA, Feyerabend C. 1982. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed) 285: 537-540.
26. Jones BE, Prada JA. 1977. Effects of methadone and morphine maintenance on drug-seeking behavior in the dog. Psychopharmacology (Berl) 54: 109-112.
27. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. 2006. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296: 56-63.
28. Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, Shoptaw S, Montgomery MA, Winhusen TM, Somoza EC, et al. 2005. Cocaine Rapid Efficacy Screening Trials (CREST): Lessons learned. Addiction 100: 102-110.
29. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. 2000. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 148: 251-262.
30. Kleven MS, Woolverton WL. 1990. Effects of continuous infusions of SCH 23390 on cocaine-or food-maintained behavior in rhesus monkeys. Behav Pharmacol 1: 365-373.
31. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R. 2007. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 164: 1115-1117.
32. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B. 1985. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1: 1014-1016.
33. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. 2005. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 30: 2103-2114.
34. Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. 2007. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31: 389-394.
35. Martin WR, Jasinski DR, Mansky PA. 1973. Naltrexone, an antagonist for the treatment of heroin dependence: Effects in man. Arch Gen Psychiatry 28: 784-791.
36. Mason BJ, Heyser CJ. 2010. Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 9: 23-32.
37. Meini M, Moncini M, Cecconi D, Cellesi V, Biasci L, Simoni G, Ameglio M, Pellegrini M, Forgione RN, Rucci P. 2011. Aripiprazole and ropinirole treatment for cocaine dependence: Evidence from a pilot study. Curr Pharm Des 17: 1376-1383.
38. Mendelson J, Jones RT. 2003. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4: 1 ratio for treatment?Drug Alcohol Depend 70: S29-37.
39. Mineur YS, Picciotto MR. 2008. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol 75: 323-333.
40. Negus SS. 2006. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: Effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther 317: 711-723.
41. O'Connor EC, Parker D, Rollema H, Mead AN. 2010. The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 208: 365-376.
42. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. 1992. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
43. Oslin DW, Berrettini WH, O'Brien CP. 2006. Targeting treatments for alcohol dependence: The pharmacogenetics of naltrexone. Addict Biol 11: 397-403.
44. Pierce RC, Kumaresan V. 2006. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30: 215-238.
45. Plant OH, Pierce IH. 1928. Studies of chronic morphin poisoning in dogs. I. General symptoms and behavior during addiction and withdrawal. J Pharmacol Exp Therapeutics 33: 329-357.
46. Platt DM, Rowlett JK, Spealman RD. 2002. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 163: 265-282.
47. Polosa R, Benowitz NL. 2011. Treatment of nicotine addiction: Present therapeutic options and pipeline developments. Trends Pharmacol Sci 32: 281-289.
48. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, et al. 1999. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56: 1101-1106.
49. Ross D, Hartmann RJ, Geller I. 1976. Ethanol preference in the hamster: Effects of morphine sulfate and naltrexone, a long-acting morphine antagonist. Proc West Pharmacol Soc 19: 326-330.
50. Russell MA, Wilson C, Feyerabend C, Cole PV. 1976. Effect of nicotine chewing gum on smoking behaviour and as an aid to cigarette withdrawal. Br Med J 2: 391-393.
51. Scott CC, Chen KK, et al. 1947. Further observations on the pharmacology of dolophine (methadon, Lilly). J Pharmacol Exp Ther 91: 147-156.
52. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
53. Thompson T, Schuster CR. 1964. Morphine self-administration, food-reinforced, and avoidance behaviors in Rhesus monkeys. Psychopharmacologia 5: 87-94.
54. Thorp RH, Walton E, Ofner P. 1947. Analgesic activity in compounds related to amidone. Nature 159: 679.
55. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. 1992. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
56. Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, Kaminsky SM, Janda KD, Crystal RG, Koob GF. 2011. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 37: 1083-1091.
57. Weeks JR. 1962. Experimental morphine addiction: Method for automatic intravenous injections in unrestrained rats. Science 138: 143-144.